文献速递腹部泌尿生殖MR

LI-RADS M(LR-M)v2018标准及报告算法在钆塞酸二钠增强MRI评估原发性肝癌中的诊断价值

LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

回顾性纳入165例病理证实的原发性肝癌高危患者,评估LI-RADS v2018的LR-M标准及报告算法在钆塞酸二钠增强MRI上的诊断效能;LR-M标准有助于鉴别非HCC恶性肿瘤与HCC并准确诊断恶性,但LR-M中报告可能病因可提高HCC检出敏感度却降低特异度。

要点

  • LR-M标准v2018有助于鉴别非HCC恶性肿瘤与HCC,并准确诊断原发性肝癌为恶性。
  • LR-M中报告可能病因可提高HCC诊断敏感度,但伴随特异度明显降低。
  • 联合LR-5与LR-M诊断恶性的敏感度显著高于LR-5联合「至少1项靶样表现的LR-M」。

核心结论

  • LR-M标准v2018有助于鉴别非HCC恶性肿瘤与HCC,并准确诊断原发性肝癌为恶性。
  • 在LR-M中报告可能病因可能促进更敏感的HCC检出,但伴随特异度明显降低。

研究设计与样本

  • 回顾性研究纳入165例HCC高危且病理证实的原发性肝癌患者(HCC n=113,肝内胆管癌 n=23,混合型肝细胞-胆管癌 n=29)。
  • 两名放射科医师独立分析钆塞酸二钠增强MRI特征,确定每个肿瘤的LI-RADS类别,并在归为LR-M时判定可能病因为HCC或非HCC恶性。
  • 按影像标准比较HCC或恶性的诊断效能。

诊断标准与关键数值

  • LR-M在肝内胆管癌中分别占95.7%/91.3%,混合型肝细胞-胆管癌中占55.2%/58.6%,HCC中占21.2%/17.7%(阅片者1/2)。
  • LR-5联合LR-M诊断原发性肝癌为恶性的敏感度为95.2%/97.6%,显著高于LR-5联合「至少1项靶样表现的LR-M」的84.8%/91.5%(P<0.01)。
  • 与LR-5相比,LR-5联合「LR-M中HCC为可能病因」诊断HCC的敏感度显著升高(73.5%/79.6% vs 87.6%/92.9%,P<0.001),但特异度显著降低(76.9%/75.0% vs 57.7%/50.0%,P=0.002和<0.001)。

临床应用与阅片要点

  • LR-M标准v2018可用于鉴别非HCC恶性肿瘤与HCC,并准确诊断原发性肝癌为恶性。
  • 在LR-M中报告可能病因可能提高HCC检出敏感度,但需注意特异度明显降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate diagnostic values of the liver imaging reporting and data system (LI-RADS) M (LR-M) category based on novel explicit criteria that accept both targetoid and nontargetoid LR-M features and the suggested reporting algorithm of LI-RADS v2018 to assess primary liver cancers (PLCs) on gadoxetic acid-enhanced MRI (Gd-EOB-MRI).

METHODS: This retrospective study included 165 patients at high risk for hepatocellular carcinoma (HCC) with pathologically confirmed PLCs (HCC, n = 113; intrahepatic cholangiocarcinoma [iCCA], n = 23; and combined hepatocellular cholangiocarcinoma [cHCC-CCA], n = 29). Two radiologists independently analyzed Gd-EOB-MRI features and determined LI-RADS category for each tumor and categorized the likely etiology either as HCC or non-HCC malignancy if LR-M was assigned. Diagnostic performances for HCC or those for malignancy were compared according to imaging criteria.

RESULTS: LR-M was assigned in 95.7%/91.3% of iCCAs; 55.2%/58.6% of cHCC-CCAs; and 21.2%/17.7% of HCCs in reviewers 1/2. Combination of LR-5 plus LR-M resulted in sensitivity of 95.2%/97.6% to diagnose PLCs as malignant, which were significantly higher than that of LR-5 plus "LR-M with ≥ 1 targetoid appearances" (84.8%/91.5%, Ps < 0.01). In comparison to LR-5, LR-5 plus "LR-M of HCC as likely etiology" resulted in significant increase in sensitivity (73.5%/79.6% versus 87.6%/92.9%, Ps < 0.001) but significant decrease in specificity (76.9%/75.0% versus 57.7%/50.0%, P = 0.002 and < 0.001) in the diagnosis of HCC.

CONCLUSION: The LR-M criteria v2018 are useful to differentiate non-HCC malignancies from HCCs and to accurately diagnose PLCs as a malignancy. Reporting the likely etiology in LR-M may facilitate a more sensitive detection of HCC, but along with a considerable decrease in specificity.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Kim MY, Joo I, Kang HJ, et al. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI. Abdom Radiol (NY). 2020. PMID: 32382817. doi:10.1007/s00261-020-02545-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。